Biohaven Ltd. (BHVN)
Upgrades & Downgrades
Latest BHVN news
These Are the Top 10 Holdings of Paul Tudor Jones
10 January 2023
Paul Tudor Jones is one of the most respected names in the hedge fund industry.
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
6 January 2023
NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
5 January 2023
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
29 November 2022
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
Biohaven CEO on 'monumental approval' of migraine drug
19 November 2022
"We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine," Biohaven CEO Vlad Coric said.
Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?
7 October 2022
Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
Biohaven Stub May Provide An Interesting Setup For Investors
6 October 2022
Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven th...
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
6 October 2022
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
Why Biohaven Stock Skyrocketed Again Today
5 October 2022
The "new" Biohaven is enjoying plenty of attention from investors.